Effects of attachment-based compassion therapy (ABCT) on brain-derived neurotrophic factor and low-grade inflammation among fibromyalgia patients : a randomized controlled trial
Montero-Marín, Jesús (RedIAPP (Red de Investigación en Actividades Preventivas y Promoción de la Salud))
Andrés Rodríguez, Laura (Universitat Autònoma de Barcelona. Departament de Psicologia Bàsica, Evolutiva i de l'Educació)
Tops, Mattie (Vrije Universiteit)
Luciano, Juan Vicente (Parc Sanitari Sant Joan de Déu)
Navarro-Gil, Mayte (Universidad de Zaragoza. Departamento de Psicología y Sociología)
Feliu-Soler, Albert (Parc Sanitari Sant Joan de Déu)
López-del-Hoyo, Yolanda (Universidad de Zaragoza. Departamento de Psicología y Sociología)
Garcia-Campayo, Javier (Hospital Universitario Miguel Servet (Saragossa))

Data:	2019
Resum:	Fibromyalgia (FM) is a disabling syndrome characterized by chronic pain associated with fatigue. Its pathogenesis is unknown, but alterations in central sensitization, involving an imbalance of brain-derived neurotrophic factor (BDNF) and inflammatory biomarkers, appear to be implicated. The aim of this study was to evaluate the impact of attachment-based compassion therapy (ABCT) on levels of BDNF, the inflammatory markers TNF-α, IL-6, IL-10, and the C-reactive protein (CRP), analysing whether biomarkers play a mediating/moderating role in improvements in FM functional status. Thirty-four female patients with FM participated in a RCT and were assigned to ABCT or relaxation therapy. Blood extractions were conducted at baseline and post-intervention, with self-report assessments of functional status (FIQ) at baseline, post-intervention and 3-month follow-up. A pro-inflammatory composite was obtained by summing up IL-6, TNF-α and CRP normalized values. Non-parametric tests, analysis of variance and regression models were used to evaluate treatment and mediation/moderation. Compared to relaxation therapy, ABCT showed significant improvements in FIQ and decreases in BDNF, CRP, and pro-inflammatory composite. Changes in BDNF had a mediating role in FIQ. ABCT seems to reduce BDNF and appears to have anti-inflammatory effects in FM patients. Reductions in BDNF could be a mechanism of FM functional status improvement. Clinical Trial Registration:http://ClinicalTrials. gov, identifier NCT02454244. Date: May 27th, 2015.
Ajuts:	Ministerio de Sanidad y Consumo RD06/0018/0017 Ministerio de Economía y Competitividad RD16/0007/0005 Ministerio de Economía y Competitividad RD16/0007/0012 Ministerio de Economía y Competitividad CP14/00087 Ministerio de Economía y Competitividad CD16/00147 Agència de Gestió d'Ajuts Universitaris i de Recerca 2018/FI_B00783
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Scientific reports, Vol. 9, núm. 1 (january 2019) , p. 15639, ISSN 2045-2322

DOI: 10.1038/s41598-019-52260-z
PMID: 31666651

14 p, 1.8 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats